Gc012f treatment for autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This early-stage trial tests a new treatment called GC012F for people with autoimmune diseases. The treatment uses your own immune cells to try to calm the overactive immune response causing your condition. It's designed to possibly reduce or stop the disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an autoimmune disease (the trial is for people with conditions like lupus, rheumatoid arthritis, or scleroderma).
- You must be between 18 and 70 years old.
- You must be willing to use effective birth control and avoid pregnancy or fathering a child for at least 2 years after the treatment, and avoid breastfeeding during that time.
- Your blood counts and organ function (like liver, kidney, and heart) need to be at a certain level for safety.
- You cannot have had CAR-T therapy or certain targeted treatments before, and you cannot have active infections like HIV, hepatitis B or C, or tuberculosis.
- You need to be in generally good health (no recent heart attacks, strokes, or major bleeding, and no other cancers in the last 5 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (GC012F) for people with idiopathic inflammatory myopathy (IIM) that hasn't responded to standard treatments. It aims to see if this treatment can help control muscle inflammation and weakness.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.